Liver dialysis in acute-on-chronic liver failure: current and future perspectives

Hepatology International

Volumn 8, Issue 2, 2014, Pages 505-513

  Maiwall, Rakhi ^a   Maras, Jaswinder Singh ^a   Nayak, Suman Lata ^a   Sarin, Shiv Kumar ^a  

^a INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

Author keywords

ACLF; Extracorporeal liver support; Liver dialysis; Plasma dialysis

Indexed keywords

BILIRUBIN; CREATININE; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; SERUM ALBUMIN; TERLIPRESSIN;

ACUTE LIVER FAILURE; ACUTE ON CHRONIC LIVER FAILURE; ALBUMIN DIALYSIS; ALCOHOL LIVER DISEASE; ARTIFICIAL LIVER; ASCITES; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; FRACTIONAL PLASMA SEPARATION AND ADSORPTION; HEMODIALYSIS; HEMOFILTRATION; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LIVER FAILURE; LIVER REGENERATION; LIVER SUPPORT; LIVER TRANSPLANTATION; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; MULTIPLE ORGAN FAILURE; OVERALL SURVIVAL; PATHOGENESIS; PLASMAPHERESIS; REVIEW; SINGLE PASS ALBUMIN DIALYSIS;

EID: 84919348331     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-014-9534-8     Document Type: Review

References (65)

1. Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009;3:269–282
2. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144:1426–1437
3. Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif. 2002;20:252–261
4. Hassanein TI, Schade RR, Hepburn IS. Acute-on-chronic liver failure: extracorporeal liver assist devices. Curr Opin Crit Care. 2011;17(2):195–203
5. Stange J, Ramlow W, Mitzner S, et al. Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs. 1993;17:809–813
6. Abe T, Shono M, Kodama T, Kita Y, Fukagawa M, Akizawa T. Extracorporeal albumin dialysis. Ther Apher Dial. 2004;8(3):217–222
7. Rozga J. Liver support technology—an update. Xenotransplantation. 2006;13(5):380–389
8. Abe T, Kobata H, Hanba Y, Kitabata Y, Narukawa N, Hasegawa H, et al. Study of plasma exchange for liver failure: beneficial and harmful effects. Ther Apher Dial. 2004;8(3):180–184
9. Falkenhagen D, Strobl W, Vogt G, Schrefl A, Linsberger I, Gerner FJ, et al. Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. Artif Organs. 1999;23(1):81–6
10. Evenepoel P, Laleman W, Wilmer A, Claes K, Kuypers D, Bammens B, et al. Prometheus versus molecular adsorbents recirculating system: comparison of efficiency in two different liver detoxification devices. Artif Organs. 2006;30:276–284
11. Krisper P, Haditsch B, Stauber R, Jung A, Stadlbauer V, Trauner M, et al. In vivo quantification of liver dialysis: comparison of albumin dialysis and fractionated plasma separation. J Hepatol. 2005;43:451–457
12. Clemmesen JO, Larsen FS, Kondrup J, Hansen BA, Ott P. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology. 1999;29:648–653
13. Mans AM, Biebuyck JF, Shelly K, Hawkins RA. Regional blood-brain barrier permeability to amino acids after portacaval anastomosis. J Neurochem. 1982;38:705–717
14. Ryska M, Laszikova E, Pantoflicek T, Ryska O, Prazak J, Koblihova E. Fractionated plasma separation and adsorption significantly decreases intracranial pressure in acute liver failure: experimental study. Eur Surg Res. 2009;42:230–235
15. Koivusalo AM, Teikari T, Höckerstedt K, Isoniemi H. Albumin dialysis has a favorable effect on amino acid profile in hepatic encephalopathy. Metab Brain Dis. 2008;23(4):387–398
16. Kobashi-Margáin RA, Gavilanes-Espinar JG, Gutiérrez-Grobe Y, et al. Albumin dialysis with molecular adsorbent recirculating system (MARS) for the treatment of hepatic encephalopathy in liver failure. Ann Hepatol. 2011;10(Suppl 2):S70–S76
17. Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology. 2002;36:949–958
18. Sen S, Davies NA, Mookerjee RP, Cheshire LM, Hodges SJ, Williams R, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl. 2004;10:1109–1119
19. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA. 2003;289(2):217–22
20. Hassanein TI, Tofteng F, Brown RS Jr, McGuire B, Lynch P, Mehta R, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007;46(6):1853–1862
21. Rifai K, Ernst T, Kretschmer U, et al. The Prometheus device for extracorporeal support of combined liver and renal failure. Blood Purif. 2005;23(4):298–302
22. Banares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology. 2013;57:1153–1162
23. Vaid A, Chweich H, Balk EM, Jaber BL. Molecular adsorbent recirculating system as artificial support therapy for liver failure: a meta-analysis. ASAIO J. 2012;58(1):51–59
24. Stenbøg P, Busk T, Larsen FS. Efficacy of liver assisting in patients with hepatic encephalopathy with special focus on plasma exchange. Metab Brain Dis. 2013;28(2):333–335
25. Nakae H, Igarashi T, Tajimi K. Selective plasma exchange with dialysis in patients with acute liver failure. Ther Apher Dial. 2012;16(5):467–471
26. Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, et al. Acute-on chronic liver failure. J Hepatol. 2012;57:1336–1348
27. Van Slambrouck CM, Salem F, Meehan SM, Chang A. Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction. Kidney Int. 2013. doi: 10.1038/ki.2013.78
28. Maiwall R, Kumar S, Vashishtha C, et al. Acute kidney injury in ACLF is different from patients with cirrhosis. Hepatology. 2013;58(S1):36A–91A
29. Angeli P, Gines P. Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice. J Hepatol. 2012;57:1135–1140
30. Kribben A, Gerken G, Haag S, Herget-Rosenthal S, Treichel U, Betz C, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology. 2012;142:782–789
31. Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl. 2000;6:277–286
32. Wong F, Raina N, Richardson R. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. Gut. 2010;59(3):381–386
33. Catalina MV, Barrio J, Anaya F, Salcedo M, Rincón D, Clemente G, et al. Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver Int. 2003;23(Suppl 3):39–43
34. Laleman W, Wilmer A, Evenepoel P, Elst IV, Zeegers M, Zaman Z, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care. 2006;10:R108
35. Sen S, Mookerjee RP, Cheshire LM, Davies NA, Williams R, Jalan R. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol. 2005;43:142–148
36. Donati G, Piscaglia F, Colì L, et al. Acute systemic, splanchnic and renal haemodynamic changes induced by molecular adsorbent recirculating system (MARS) treatment in patients with end-stage cirrhosis. Aliment Pharmacol Ther. 2007;26(5):717–726
37. A Khanam, N Trehanpati, V Garg et al. Altered frequencies of dendritic cells and IFN-c-secreting T cells with granulocyte colony-stimulating factor (G-CSF) therapy in acute-on-chronic liver failure. Liver Int. 2014;34(4):505–513
38. Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghoner A, Vidacek D, Siewert E, et al. Patients with ACLF display “sepsis-like” immune paralysis. J Hepatol. 2005;42:195–201
39. Guo LM, Liu JY, Xu DZ, Li BS, Han H, Wang LH, et al. Application of molecular adsorbents recirculating system to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Int. 2003;23(Suppl 3):16–20
40. Jalan R, Schnurr K, Mookerjee RP, Sen S, Cheshire L, Hodges S, et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology. 2009;50:555–564
41. Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013;58(5):1836–1846
42. Rocen M, Kieslichova E, Merta D, Uchytilova E, Pavlova Y, Cap J, et al. The effect of Prometheus device on laboratory markers of inflammation and tissue regeneration in acute liver failure management. Transpl Proc. 2010;42(9):3606–3612
43. Donati G, La Manna G, Cianciolo G, Grandinetti V, Carretta E, Cappuccilli M, et al. Extracorporeal detoxification for hepatic failure using molecular adsorbent recirculating system: depurative efficiency and clinical results in a long-term follow-up. Artif Organs. 2013;38(2):125–134
44. Nakamura T, Sakai K, Nakamura T, Matsumoto K. Hepatocyte growth factor twenty years on: much more than a growth factor. J Gastroenterol Hepatol. 2011;26(Suppl 1):188–202
45. Khuroo MS, Khuroo MS, Farahat KL. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl. 2004;10(9):1099–1106
46. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA. 2003;289(2):217–222
47. Liu J, Kjaergard LL, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for liver failure: a Cochrane Hepato-Biliary Group Protocol. Liver. 2002;22(5):433–438
48. Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol. 2003;38:24–31
49. Faenza S, Baraldi O, Bernardi M, Bolondi L, Coli L, Cucchetti A, et al. Mars and Prometheus: our clinical experience in acute chronic liver failure. Transplant Proc. 2008;40(4):1169–71
50. Ling Q, Xu X, Wei Q, Liu X, Guo H, Zhuang L, et al. Downgrading MELD improves the outcomes after liver transplantation in patients with acute-on-chronic hepatitis B liver failure. PLoS One. 2012;7(1):e30322
51. Wai CT, Lim SG, Aung MO, Lee YM, Sutedja DS, Dan YY, Aw MM, Quak SH, Lee MK, Da Costa M, Prahbakaran K, Lee KH. MARS: a futile tool in centres without active liver transplant support. Liver Int. 2007;27(1):69–75
52. Hessel FP, Bramlage P, Wasem J, Mitzner SR. Cost-effectiveness of the artificial liver support system MARS in patients with acute-on-chronic liver failure. Eur J Gastroenterol Hepatol. 2010;22(2):213–220
53. Hessel FP, Mitzner SR, Rief J, Guellstorff B, Steiner S, Wasem J. Economic evaluation and 1-year survival analysis of MARS in patients with alcoholic liver disease. Liver Int. 2003;23(Suppl 3):66–72
54. Hessel FP. Economic evaluation of the artificial liver support system MARS in patients with acute-on-chronic liver failure. Cost Eff Resour Alloc. 2006;4:16
55. Kantola T, Mäklin S, Koivusalo AM, Räsänen P, Rissanen A, Roine R, et al. Cost-utility of molecular adsorbent recirculating system treatment in acute liver failure. World J Gastroenterol. 2010;16(18):2227–2234
56. Brown K. Liver Dialysis: Molecular Adsorbent Recirculating System (MARS) BME 281 Second Presentation, November 27, 2012
57. Weber V, Linsberger I, Hauner M, et al. Neutral styrene divinylbenzene copolymers for adsorption of toxins in liver failure. Biomacromolecules. 2008;9(4):1322–1328. doi:10.1021/bm701396n
58. Dominik A, Stange J, Pfensig C, Borufka L, Weiss-Reining H, Eggert M. Reduction of elevated cytokine levels in acute/acute-on-chronic liver failure using super-large pore albumin dialysis treatment: an in vitro study. Ther Apher Dial. 2013. doi:10.1111/1744-9987.12146
59. He CS, Shi W, Ye ZM, Liang XL, Zhang B, Liu SX, et al. Efficacy and safety of coupled plasma filtration adsorption combined with continuous veno-venoushemofiltration for multiple organ dysfunction syndrome patients with acute liver failure. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2007;19(1):47–49
60. Marangoni R, Bellati G, Castelli A, Romagnoli E. Development of high-efficiency molecular adsorbent recirculating system: preliminary report. Artif Organs. 2014. doi:10.1111/aor.12250
61. Novelli G, Morabito V, Pugliese F, Ferretti G, Novelli S, Ianni S, et al. Management of sepsis during MARS treatment in ACLF. Transpl Proc. 2011;43:1085–1090
62. Komura T, Taniguchi T, Sakai Y, Yamashita T, Mizukoshi E, Noda T, et al. Efficacy of continuous plasma diafiltraion therapy in critical patients with acute liver failure. J Gastroenterol Hepatol. 2014;29(4);782–786 doi:10.1111/jgh.12440
63. Peszynski P, Klammt S, Peters E, et al. Albumin dialysis: single pass vs.recirculation (MARS). Liver. 2002;22(Suppl 2):40–42
64. Rademacher S, Oppert M, Jörres A. Artificial extracorporeal liver support therapy in patients with severe liver failure. Expert Rev Gastroenterol Hepatol. 2011;5(5):591–599. doi:10.1586/egh.11.59
65. Xu X, Liu X, Ling Q, Wei Q, Liu Z, Xu X, et al. Artificial liver support system combined with liver transplantation in the treatment of patients with acute-on-chronic liver failure. PLoS One. 2013;8(3):e58738